Decreased breath excretion of redox active iron in COPD: A protective failure?

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1267-1270

  Mumby, Sharon ^a   Saito, Junpei ^a   Adcock, Ian M ^a   Chung, Kian Fan ^a   Quinlan, Gregory J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN; HEPCIDIN; INTERLEUKIN 6; IRON; REDOX ACTIVE IRON; UNCLASSIFIED DRUG; BLEOMYCIN; IL6 PROTEIN, HUMAN; OXIDIZING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; EXCRETION; EXHALED BREATH CONDENSATE; EXPIRED AIR; HUMAN; IRON DEFICIENCY; IRON KINETICS; IRON METABOLISM; LETTER; MACROPHAGE; PRIORITY JOURNAL; SMOKING; BLOOD; BREATH ANALYSIS; CASE CONTROL STUDY; CHEMISTRY; EXHALATION; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

BLEOMYCIN; BREATH TESTS; CASE-CONTROL STUDIES; EXHALATION; HEPCIDINS; HUMANS; INTERLEUKIN-6; IRON; OXIDANTS; OXIDATION-REDUCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; SMOKING;

EID: 84964053113     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01710-2015     Document Type: Letter

References (15)

1. Silverberg DS, Mor R, Weu MT, et al. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014; 14: 24.
2. Chappell SL, Daly L, Lotya J, et al. The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: A replication case-control study. BMC Med Genet 2011; 12: 24.
3. Mumby S, Chung KF, McCreanor JE, et al. Pro-oxidant iron in exhaled breath condensate: A potential excretory mechanism. Respir Med 2011; 105: 1290-1295.
4. Gutteridge JM, Mumby S, Quinlan GJ, et al. Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in the lung. Biochem Biophys Res Commun 1996; 220: 1024-1027.
5. Ghio AJ, Hilborn ED, Stonehuerner JG, et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit Care Med 2008; 178: 1130-1138.
6. Gutteridge JM, Rowley DA, Halliwell B, et al. Copper and iron complexes catalytic for oxygen radical reactions in sweat from human athletes. Clin Chim Acta 1985; 145: 267-273.
7. Philippot Q, Deslée G, Adair-Kirk TL, et al. Increased iron sequestration in alveolar macrophages in chronic obstructive pulmonary disease. PLoS One 2014; 9: e96285.
8. Miseta A, Nagy J, Nagy T, et al. Hepcidin and its potential clinical utility. Cell Biol Int 2015; 39: 1191-1202.
9. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 2014; 35: 155-161.
10. Yang F, Haile DJ, Wang X, et al. Apical location of ferroportin 1 in airway epithelia and its role in iron detoxification in the lung. Am J Physiol Lung Cell Mol Physiol 2005; 289: L14-L23.
11. Duru S, Bilgin E, Ardic S. Hepcidin: A useful marker in chronic obstructive pulmonary disease. Ann Thorac Med 2012; 7: 31-35.
12. Mackay AJ, Loza M, Branigan PJ, et al. Serum amyloid A and hepcidin elevations characterize bacterial-associated exacerbations in frequently exacerbating COPD patients. Am J Respir Crit Care Med 2015; 191: A6363.
13. Nickol AH, Frise MC, Cheng HY, et al. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease. BMJ Open 2015; 5: e007911.
14. Tandara L, Grubisic TZ, Ivan G, et al. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin Biochem 2015; 48: 1252-1257.
15. Mutti A, Corradi M, Goldoni M, et al. Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest 2006; 129: 1288-1297.